Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Summary

The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease. All patients will receive 200 mg of camrelizumab intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to 18 cycles.

Timeline

Start

2020-01-01

Primary completion

2024-02-01

Completion

2024-02-01

Drugs

Indications